Manchester Capital Management LLC purchased a new stake in shares of Horizon Therapeutics PLC (NASDAQ:HZNP) in the first quarter, HoldingsChannel.com reports. The institutional investor purchased 1,568 shares of the biopharmaceutical company’s stock, valued at approximately $41,000.
Several other institutional investors and hedge funds have also modified their holdings of the company. BlackRock Inc. lifted its holdings in shares of Horizon Therapeutics by 2.0% during the fourth quarter. BlackRock Inc. now owns 13,896,831 shares of the biopharmaceutical company’s stock valued at $271,544,000 after purchasing an additional 266,698 shares in the last quarter. D. E. Shaw & Co. Inc. lifted its position in Horizon Therapeutics by 63.8% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 3,369,508 shares of the biopharmaceutical company’s stock valued at $65,840,000 after purchasing an additional 1,312,142 shares during the period. Norges Bank acquired a new stake in Horizon Therapeutics in the fourth quarter valued at about $46,493,000. Jennison Associates LLC lifted its position in Horizon Therapeutics by 57.1% in the fourth quarter. Jennison Associates LLC now owns 2,220,567 shares of the biopharmaceutical company’s stock valued at $43,390,000 after purchasing an additional 807,401 shares during the period. Finally, FMR LLC lifted its position in Horizon Therapeutics by 361.8% in the fourth quarter. FMR LLC now owns 1,963,146 shares of the biopharmaceutical company’s stock valued at $38,360,000 after purchasing an additional 1,538,056 shares during the period. Hedge funds and other institutional investors own 85.98% of the company’s stock.
In related news, EVP Geoffrey M. Curtis sold 10,080 shares of Horizon Therapeutics stock in a transaction on Monday, February 25th. The shares were sold at an average price of $21.21, for a total transaction of $213,796.80. Following the transaction, the executive vice president now owns 35,367 shares in the company, valued at approximately $750,134.07. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 4.10% of the company’s stock.
NASDAQ:HZNP opened at $24.83 on Friday. The company has a current ratio of 1.74, a quick ratio of 1.68 and a debt-to-equity ratio of 0.90. The firm has a market cap of $4.59 billion, a P/E ratio of 13.57 and a beta of 1.09. Horizon Therapeutics PLC has a twelve month low of $15.60 and a twelve month high of $29.44.
Horizon Therapeutics (NASDAQ:HZNP) last posted its earnings results on Wednesday, May 8th. The biopharmaceutical company reported $0.30 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.10 by $0.20. The business had revenue of $280.00 million for the quarter, compared to analyst estimates of $238.35 million. Horizon Therapeutics had a net margin of 3.79% and a return on equity of 33.57%. The business’s quarterly revenue was up 25.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.03 EPS. Sell-side analysts forecast that Horizon Therapeutics PLC will post 1.64 EPS for the current year.
A number of equities research analysts have recently issued reports on the stock. BidaskClub downgraded shares of Horizon Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 20th. Zacks Investment Research raised shares of Horizon Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, January 25th. Jefferies Financial Group boosted their price objective on shares of Horizon Therapeutics to $34.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Cowen set a $33.00 target price on shares of Horizon Therapeutics and gave the company a “buy” rating in a report on Thursday, February 28th. Finally, Morgan Stanley upgraded shares of Horizon Therapeutics from an “equal weight” rating to an “overweight” rating and set a $32.00 target price on the stock in a report on Friday, March 8th. Four research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Horizon Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $30.83.
WARNING: This piece was posted by Stock Observer and is the property of of Stock Observer. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.thestockobserver.com/2019/05/25/manchester-capital-management-llc-invests-41000-in-horizon-therapeutics-plc-hznp.html.
About Horizon Therapeutics
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Therapeutics PLC (NASDAQ:HZNP).
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.